Spring Bank Pharmaceuticals Stockholders Approve Combination with F-star Therapeutics
19 nov. 2020 17h00 HE
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for...
Spring Bank Pharmaceuticals Announces Special Dividend of Contingent Value Rights
06 nov. 2020 17h01 HE
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for...
Spring Bank Announces Poster Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
02 nov. 2020 08h00 HE
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and...
Spring Bank Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Results
10 août 2020 16h00 HE
|
Spring Bank Pharmaceuticals, Inc.
Announced agreement for strategic combination with F-star Therapeutics to advance a pipeline of multiple clinical-stage immuno-oncology programs Continued to advance IV SB 11285 clinical trial to...
Spring Bank Pharmaceuticals and F-star Therapeutics Agree to Combine to Pursue Mission of Creating Next Generation Immunotherapies
29 juil. 2020 16h27 HE
|
Spring Bank Pharmaceuticals, Inc.
Combined company will operate as F-star Therapeutics and advance pipeline of multiple clinical-stage immuno-oncology programsCombined company expected to have at least $40 million in cash prior to...
Spring Bank Advances IV SB 11285 Clinical Program
03 juin 2020 08h00 HE
|
Spring Bank Pharmaceuticals, Inc.
- Safety Review Committee for IV SB 11285 Phase 1a/1b trial recommends dose escalation to next planned monotherapy dose level and initiation of first co-administration dose level with Roche’s PD-L1...
Spring Bank to Present at the Jefferies Virtual Global Healthcare Conference
26 mai 2020 16h30 HE
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Announces Poster Presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
20 mai 2020 07h00 HE
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Pharmaceuticals Reports First Quarter 2020 Financial and Operational Results
07 mai 2020 16h30 HE
|
Spring Bank Pharmaceuticals, Inc.
Continues to advance IV SB 11285 clinical trial to additional dosing cohorts On track to include Roche’s Tecentriq® in IV SB 11285 clinical trial in summer 2020 Advancing efforts to examine RIG-I...
Spring Bank Provides Update on Business Operations & Clinical Program Progress During COVID-19 Pandemic
02 avr. 2020 08h00 HE
|
Spring Bank Pharmaceuticals, Inc.
Pursuing collaborations to develop internal compounds for potential treatment of COVID-19Safety Review Committee for IV SB 11285 Phase 1a/1b trial recommends dose escalation to next planned dose...